http://www.cnr.it/ontology/cnr/individuo/prodotto/ID11977

Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the nsLTP plant family (Articolo in rivista)

Type

Label

Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the nsLTP plant family (Articolo in rivista) (literal)

Anno

Alternative label

BONURA A.,AMOROSO S.,LOCOROTONDO G.,DI FELICE G., TINGHINO R.,GERACI D. AND COLOMBO P. (2001)
Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the nsLTP plant family
in International archives of allergy and immunology
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

BONURA A.,AMOROSO S.,LOCOROTONDO G.,DI FELICE G., TINGHINO R.,GERACI D. AND COLOMBO P. (literal)

Pagina inizio

Pagina fine

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

I dati riportati in questo lavoro rappresentano il primo esempio di allergeni del polline di Parietaria modificati mediante tecniche di biologia molecolare. La caratterizzazione di tale molecole apre nuovi scenari e nuovi orizzonti terapeutici per la cura dell'allergia di questa sorgente pollinica. (literal)

Note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

Titolo

Hypoallergenic variants of the Parietaria judaica major allergen Par j 1: a member of the nsLTP plant family (literal)

Abstract

Par j 1 represents a major allergenic component of Parietaria judaica (Pj) pollen, since it is able to induce an immunoglobulin E (IgE) response in 95% of Pj-allergic patients. It belongs to the non-specific lipid transfer protein family, sharing with them a common three-dimensional structure. METHODS: Disulphide bond variants of the recombinant Par j 1 (rPar j 1) allergen were generated by site-directed mutagenesis, and the immunological activity of rPar j 1 and its conformational mutants was compared with the use of the skin prick test (SPT). The ability to bind IgE antibodies was evaluated by Western blot, ELISA and ELISA inhibition. T cell reactivity was measured by peripheral blood mononuclear cell proliferation assay. RESULTS: The disruption of Cys14-Cys29 and Cys30-Cys75 bridging (PjA mutant) caused the loss of the majority of specific IgE-binding activity. Additional disruption of the Cys4-Cys52 bridge (PjC mutant) and the latter Cys50-Cys91 bridge (PjD mutant) led to the abolition of IgE-binding activity. On the SPT, PjB (lacking the Cys4-Cys52 and Cys50-Cys91 bridges) was still capable of triggering a type I hypersensitive reaction in 9 out of 10 patients, and PjA in 3 out of 10 patients, while PjC and PjD did not show any SPT reactivity. All the mutants preserved their T cell reactivity. CONCLUSION: Recombinant hypoallergenic variants of the rPar j 1 allergen described herein may represent a useful tool for improved immunotherapy. (literal)

Prodotto di